Advances in the treatment of newly diagnosed glioblastoma. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Theeler, Brett; Gilbert, Mark
• Is Part Of: BMC medicine. Volume 13:Issue 1(2015)
• Page Start: 1
• Page End: 11
• Publication Date: 2015-12
• Subjects: Glioblastoma -- High grade glioma -- Immunotherapy -- Checkpoint inhibitors -- Pseudoprogression; Medicine -- Periodicals; 610.5
• DOI: 10.1186/s12916-015-0536-8
• Languages: English
• ISSNs: 1741-7015

Abstract

Abstract Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using the experience from recently completed large scale, multi-faceted, randomized glioblastoma clinical trials, a new clinical trial paradigm is being established to move promising therapies forward into the newly diagnosed treatment setting. Upcoming trials using the immune check-point inhibitors are an example of this changing paradigm and these and other immunotherapies have potential as promising new treatment modalities for newly diagnosed GB patients.